{"createdAt":"8/2/2020, 2:37:54 PM","timestamp":1596393474958,"Company ID number":"654","DMX_ISSUER_NAME":"Zhejiang CONBA Pharmaceutical Co., Ltd.","DMX_ISSUER_ID":"IID000000002134930","Country of Classification":"CHINA","name":"Zhejiang CONBA Pharmaceutical Co Ltd ","code":"600572","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"浙江康恩贝制药股份有限公司_胡季强","group":"board","name":"胡季强","title":"董事长,董事","isMale":true,"age":"59","degree":"博士","salary":"22.14万","stockAmount":"1.761亿","description":"胡季强,中国籍,男,1961年2月生,浙江医科大学药学系本科毕业,工商管理博士,中共党员,执业药师、药学专业教授级高级工程师,享受国务院批准的政府特殊津贴。曾为第十二届全国人民代表大会代表,并曾担任浙江康恩贝制药股份有限公司第三届至第九届董事会董事长、总裁,康恩贝集团有限公司董事长。现为第十三届全国人民代表大会代表,并任浙江康恩贝制药股份有限公司第十届董事会董事长,浙江博康医药投资有限公司董事长,康恩贝集团有限公司董事长、党委书记,云南喜满家生物谷发展有限公司董事长、浙江现代中药与天然药物研究院有限公司董事长、东阳市咱老家投资有限公司执行董事、云南康麻生物科技有限公司董事。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_罗国良","group":"board","name":"罗国良","title":"副董事长,董事","isMale":true,"age":"58","degree":"硕士","salary":"--","stockAmount":"-","description":"罗国良,中国籍,男,1962年11月生,中国药科大学药学专业大专学历,新加坡国立大学企业管理学院工商管理硕士学位,中共党员,高级经济师、副主任中药师,杭州市下城区政协委员。曾任浙江省医药药材公司副总经理、总经理,上海美罗医药公司总经理,大连美罗药业股份有限公司总经理,浙江省医药工业有限责任公司总经理,浙江英特药业有限责任公司常务副总经理、总经理,浙江英特集团股份有限公司常务副总经理、总经理、党委副书记、董事,浙江英特药业有限责任公司董事长。现任浙江康恩贝制药股份有限公司第十届董事会副董事长、总裁。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_谌明","group":"board","name":"谌明","title":"董事","isMale":true,"age":"44","degree":"硕士","salary":"--","stockAmount":"-","description":"谌明,中国籍,男,1976年12月生,南京农业大学土地资源管理专业研究生学历,管理学硕士学位,中共党员,高级会计师。曾任浙江天健会计师事务所高级项目经理、中化蓝天集团有限公司财务部副总经理、浙江蓝天环保高科技股份有限公司财务总监、中化太仓化工产业园财务总监等职务,浙江英特集团股份有限公司党委委员、财务总监。现任浙江康恩贝制药股份有限公司第十届董事会董事,财务负责人、财务总监。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_程兴华","group":"board","name":"程兴华","title":"董事","isMale":true,"age":"57","degree":"博士","salary":"--","stockAmount":"-","description":"程兴华,中国籍,男,1963年6月生,上海财经大学经济学博士,浙江大学理论经济学博士后,高级经济师,副研究员。曾任浙商金汇信托股份有限公司董事、董事会法务总监、总经理,浙江省国际贸易集团有限公司金融产业部总经理等职务。现任浙江省国际贸易集团有限公司投资管理部总经理、浙江康恩贝制药股份有限公司第十届董事会董事。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_胡北","group":"board","name":"胡北","title":"董事","isMale":true,"age":"33","degree":"硕士","salary":"32.45万","stockAmount":"-","description":"胡北,中国籍,男,1987年10月生,英国曼彻斯特大学研究生毕业,曾任康恩贝集团有限公司总裁助理、副总裁,浙江宝芝林中药科技有限公司总经理,浙江康恩贝制药股份有限公司第九届董事会董事、副总裁。现任康恩贝集团有限公司董事、浙江至心医药投资有限公司董事长、浙江康恩贝健康科技有限公司总经理、浙江凤登环保股份有限公司董事、浙江康恩贝制药股份有限公司第十届董事会董事。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_杨俊德","group":"board","name":"杨俊德","title":"董事","isMale":true,"age":"60","degree":"硕士","salary":"82.79万","stockAmount":"25.8万","description":"杨俊德,中国籍,男,1960年2月生,武汉工学院管理工程系硕士研究生学历。曾任浙江省经济建设规划院所属省工程咨询公司外资部、咨询评估部副主任、主任,浙江浙经资产评估公司资产评估部、投资咨询部主任,浙江康恩贝制药股份有限公司投资管理部经理、第四届至九届董事会秘书、副总裁,浙江佐力药业股份有限公司董事。现任浙江康恩贝制药股份有限公司第十届董事会董事、云南康麻生物科技有限公司监事。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_汪洋","group":"board","name":"汪洋","title":"董事","isMale":false,"age":"39","degree":"博士","salary":"--","stockAmount":"-","description":"汪洋,中国籍,女,1981年4月生,第二军医大学生药学专业博士毕业,医学博士学位,副主任中药师,执业中药师,现为杭州市第十三届人民代表大会代表。曾担任浙江英特医药药材有限公司总经理、浙江钱王中药有限公司董事长兼总经理。现任浙江省中医药健康产业集团有限公司副总经理、浙江康恩贝制药股份有限公司第十届董事会董事。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_刘恩","group":"board","name":"刘恩","title":"独立董事","isMale":true,"age":"57","degree":"博士","salary":"--","stockAmount":"-","description":"刘恩,中国籍,男,1963年7月生,中共党员,华东政法学院本科学历,博士学位,一级律师。曾就职于浙杭律师事务所(原杭州市第一律师事务所),2009年至今,就职于浙江智仁律师事务所,现任浙江智仁律师事务所合伙人会议主席,兼任杭州市律师协会党委委员、副会长,杭州师范大学法学院客座教授,杭州仲裁委员会仲裁员,浙江省法学会中小企业法研究会副会长,中国法学会律师法学研究会特邀研究员,并任浙江康恩贝制药股份有限公司第十届董事会独立董事。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_吴永江","group":"board","name":"吴永江","title":"独立董事","isMale":true,"age":"58","degree":"博士","salary":"--","stockAmount":"-","description":"吴永江,中国籍,男,1962年10月生,民进会员,浙江大学博士研究生,浙江大学药学院教授。曾任浙江医科大学讲师、副教授,1998年9月至今在浙江大学任教,现任浙江大学现代中药研究所所长、药物分析学教授、博士生导师,兼任泽达易盛(天津)科技股份有限公司董事、杭州泽达健康科技有限公司董事、苏州泽达慧康医药科技有限公司董事、天津泽达天健科技有限公司监事、苏州泽达兴邦医药科技有限公司监事、洛阳泽达慧康医药科技有限公司监事,并任浙江康恩贝制药股份有限公司第十届董事会独立董事。主要研究领域包括中药药效物质基础、中药质量分析、中药先进制造及全程质量控制等。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_吕久琴","group":"board","name":"吕久琴","title":"独立董事","isMale":false,"age":"54","degree":"博士","salary":"--","stockAmount":"-","description":"吕久琴,中国籍,女,1966年9月生,民盟盟员,复旦大学毕业,研究生学历,博士学位,中国注册资产评估师,杭州电子科技大学会计学院教授、硕导。曾任河南轻工业干部学校助教、讲师,武汉理工大学副教授、硕导,2007年5月至今在杭州电子科技大学会计学院任教,并任浙江康恩贝制药股份有限公司第十届董事会独立董事。主要研究领域包括财税政策、政府补贴、企业研发投资及创新等。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_董作军","group":"board","name":"董作军","title":"独立董事","isMale":true,"age":"50","degree":"博士","salary":"--","stockAmount":"-","description":"董作军,中国籍,男,1970年3月生,中共党员,中国药科大学毕业,研究生学历,博士学位,获得执业律师资格。曾任浙江省食品药品监督管理局副处长,2013年11月至今任浙江工业大学讲师,2016年11月至今任浙江莎普爱思药业股份有限公司独立董事,并任浙江康恩贝制药股份有限公司第十届董事会独立董事。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_应春晓","group":"supervisoryCommittee","name":"应春晓","title":"监事会主席","isMale":false,"age":"46","degree":"硕士","salary":"--","stockAmount":"-","description":"应春晓,中国籍,女,1974年4月出生,华东政法大学本科学历,浙江大学硕士研究生学位,中共党员。曾任浙江英特集团股份有限公司党委副书记、纪委书记、工会主席,曾任浙江省中医药健康产业集团有限公司党委副书记、副董事长、总经理,现任浙江康恩贝制药股份有限公司第十届监事会主席。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_吴仲时","group":"supervisoryCommittee","name":"吴仲时","title":"监事","isMale":true,"age":"57","degree":"硕士","salary":"0.00","stockAmount":"20.19万","description":"吴仲时,中国籍,男,1963年7月生,杭州商学院财会专业本科学历,上海财经大学硕士,中共党员,副教授。曾担任浙江康恩贝制药股份有限公司第六届至第八届董事会董事、副董事长,浙江康恩贝制药股份有限公司第九届监事会主席,康恩贝集团有限公司董事、副总裁、财务总监。现任康恩贝集团有限公司董事、总裁、财务总监,江西龙虎山丹霞国际养生谷有限公司董事长,兰溪市兰信小额贷款有限责任公司董事,浙江凤登环保股份有限公司董事,仙鹤纸业股份有限公司独立董事,云南康麻生物科技有限公司董事,并任浙江康恩贝制药股份有限公司第十届监事会监事。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_叶剑锋","group":"supervisoryCommittee","name":"叶剑锋","title":"职工监事","isMale":true,"age":"47","degree":"博士","salary":"--","stockAmount":"-","description":"叶剑锋,中国籍,男,1973年9月生,浙江大学生物医学工程博士,教授级高级工程师。曾担任康恩贝集团有限公司研发部高级经理、浙江康恩贝制药股份有限公司研发部经理、现代中药与天然药物研究院科技监管部总经理、浙江康恩贝药品研究开发有限公司总经理。现任浙江康恩贝制药股份有限公司植物药事业部总经理、浙江康恩贝医药销售有限公司总经理、内蒙古康恩贝药业有限公司总经理。","lastUpdated":"2020-07-14"},{"id":"浙江康恩贝制药股份有限公司_罗国良","group":"manager","name":"罗国良","title":"总裁","isMale":true,"age":"58","degree":"硕士","salary":"--","stockAmount":"-","description":"罗国良,中国籍,男,1962年11月生,中国药科大学药学专业大专学历,新加坡国立大学企业管理学院工商管理硕士学位,中共党员,高级经济师、副主任中药师,杭州市下城区政协委员。曾任浙江省医药药材公司副总经理、总经理,上海美罗医药公司总经理,大连美罗药业股份有限公司总经理,浙江省医药工业有限责任公司总经理,浙江英特药业有限责任公司常务副总经理、总经理,浙江英特集团股份有限公司常务副总经理、总经理、党委副书记、董事,浙江英特药业有限责任公司董事长。现任浙江康恩贝制药股份有限公司第十届董事会副董事长、总裁。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_金祖成","group":"manager","name":"金祖成","title":"董事会秘书","isMale":true,"age":"45","degree":"硕士","salary":"--","stockAmount":"-","description":"金祖成,中国籍,男,1975年2月生,天津医科大学临床医学专业本科、浙江大学工商管理硕士。曾任职浙江医院、InternationalSOS(国际SOS紧急救援中心)从事临床医生工作,浙江康恩贝医药销售有限公司、浙江华海药业从事市场营销工作,任浙江京新药业股份有限公司董事、董事会秘书,任康恩贝集团有限公司董事长助理兼董事长办公室主任,任浙江康恩贝制药股份有限公司董事长助理兼投资总监。现任浙江康恩贝制药股份有限公司第十届董事会秘书。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_袁振贤","group":"manager","name":"袁振贤","title":"副总裁","isMale":false,"age":"44","degree":"硕士","salary":"52.69万","stockAmount":"3万","description":"袁振贤,中国籍,女,1976年11月生,浙江大学本科学历,会计硕士学位,高级会计师,中共党员。曾历任浙江康恩贝医药销售有限公司财务总监,康恩贝集团有限公司财务管理中心副总经理兼财务审计部部长,及浙江康恩贝制药股份有限公司财务总监、财务负责人、副总裁。现任浙江康恩贝制药股份有限公司副总裁。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_徐春玲","group":"manager","name":"徐春玲","title":"副总裁","isMale":false,"age":"52","degree":"本科","salary":"33.08万","stockAmount":"-","description":"徐春玲,中国籍,女,1968年10月生,浙江工业大学轻工业工程系本科毕业,生物医药专业正高级工程师、执业药师,中共党员。曾在浙江康恩贝医药销售有限公司、康恩贝集团公司、浙江康恩贝制药股份有限公司历任部门副经理、经理、质量总监、总经理助理、副总经理等职务,任杭州康恩贝制药有限公司总经理职务,及浙江康恩贝制药股份有限公司副总裁职务。现任康恩贝集团公司党委副书记、纪委书记,杭州康恩贝制药有限公司董事长,浙江康恩贝制药股份有限公司副总裁。","lastUpdated":"2020-07-23"},{"id":"浙江康恩贝制药股份有限公司_谌明","group":"manager","name":"谌明","title":"财务负责人,财务总监","isMale":true,"age":"44","degree":"硕士","salary":"--","stockAmount":"-","description":"谌明,中国籍,男,1976年12月生,南京农业大学土地资源管理专业研究生学历,管理学硕士学位,中共党员,高级会计师。曾任浙江天健会计师事务所高级项目经理、中化蓝天集团有限公司财务部副总经理、浙江蓝天环保高科技股份有限公司财务总监、中化太仓化工产业园财务总监等职务,浙江英特集团股份有限公司党委委员、财务总监。现任浙江康恩贝制药股份有限公司第十届董事会董事,财务负责人、财务总监。","lastUpdated":"2020-07-23"}],"companyName":"浙江康恩贝制药股份有限公司","province":"浙江省","englishName":"Zhejiang CONBA Pharmaceutical Co., Ltd.","industry":"医药生物 — 中药Ⅱ","website":"www.conbagroup.com","mainBusiness":"药品的研发、生产和销售","productsName":["现代中药与植物药","化学药品","大健康产品","原料药"],"actualController":"浙江省人民政府国有资产监督管理委员会","actualControllerSharePercentage":"18.00%","registeredCapital":"26.67亿元","employeeAmount":"9513","phone":"86-0571-87774710;86-0571-87774828","location":"浙江省杭州市滨江区高新技术开发区滨江科技经济园滨康路568号","chineseDescription":"浙江康恩贝制药股份有限公司是一家主要从事药品的生产、销售和研发销售业务的公司.公司的主导产品为前列康牌普乐安片与胶囊、天保宁牌银杏叶片、天保康牌葛根素注射液、康恩贝牌刻停片、乌灵胶囊.公司系国家中药五十强企业,为国家科技部认定的火炬计划重点高新技术企业.公司及子公司均已全面通过GMP认证或GSP认证.2010年,申请国家发明专利10项,获国家发明专利授权6项;申报省级以上科技项目21项,其中国家级5项,其中\"银杏叶制剂生产过程质量控制先进技术产业化示范\"项目获批国家发改委中药产业化专项,\"银杏叶关键技术研究与国际认证\"获批国家发改委、科技部\"十二五\"重大新药创新项目立项.新立项研发项目28项,...查看全部▼浙江康恩贝制药股份有限公司是一家主要从事药品的生产、销售和研发销售业务的公司.公司的主导产品为前列康牌普乐安片与胶囊、天保宁牌银杏叶片、天保康牌葛根素注射液、康恩贝牌刻停片、乌灵胶囊.公司系国家中药五十强企业,为国家科技部认定的火炬计划重点高新技术企业.公司及子公司均已全面通过GMP认证或GSP认证.2010年,申请国家发明专利10项,获国家发明专利授权6项;申报省级以上科技项目21项,其中国家级5项,其中\"银杏叶制剂生产过程质量控制先进技术产业化示范\"项目获批国家发改委中药产业化专项,\"银杏叶关键技术研究与国际认证\"获批国家发改委、科技部\"十二五\"重大新药创新项目立项.新立项研发项目28项,总在研项目80余项,其中创新药物19项.中药六类新药黄莪胶囊通过技术审评,生产批件已在审批阶段.中药五类新药菊花舒心片启动Ⅱa期临床试验.完成化药三类新药瑞舒伐他汀钙原料及片剂临床试验.7个产品申报注册获受理.获得药品生产批件3项和保健食品生产批件1项。收起▲","foundedDate":"1993-01-09","goPublicDate":"2004-04-12","companyHistory":"浙江康恩贝制药股份有限公司（以下简称公司或本公司）的前身为兰溪云山制药厂，成立于1969年，1990年更名为浙江康恩贝制药公司。1992年6月5日，经浙江省股份制试点工作协调小组浙股（1992）5号文批准，原浙江康恩贝制药公司改组为浙江康恩贝股份有限公司，并于1993年1月9日在浙江省工商行政管理局办妥登记手续。1999年10月27日，公司更名为浙江康恩贝制药股份有限公司。公司现持有统一社会信用代码为91330000142924161N的营业执照，注册资本2,510,730,000.00元，股份总数2,510,730,000股（每股面值1元）。其中：有限售条件的流通A股452,991,900股，无限售条件的流通A股2,057,738,100股。公司股票已于2004年4月12日在上海证券交易所挂牌交易。\n　　本公司属制药行业。主要经营活动为药品的研发、生产和销售。收起▲","shareholders":[{"organizationId":"03148564","holderName":"康恩贝集团有限公司","totalShare":"7.07亿","sharePercentage":"26.52%"},{"organizationId":"","holderName":"胡季强","totalShare":"1.76亿","sharePercentage":"6.60%"},{"organizationId":"T000073058","holderName":"中国证券金融股份有限公司","totalShare":"1.17亿","sharePercentage":"4.38%"},{"organizationId":"","holderName":"金元顺安基金-杭州银行-华润信托-华润信托·汇祥增利53号单一资金信托","totalShare":"3185.55万","sharePercentage":"1.19%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"2361.62万","sharePercentage":"0.89%"},{"organizationId":"","holderName":"陈丽君","totalShare":"2338.36万","sharePercentage":"0.88%"},{"organizationId":"T000738049","holderName":"浙江大华投资发展有限公司","totalShare":"2300.00万","sharePercentage":"0.86%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"1790.51万","sharePercentage":"0.67%"},{"organizationId":"","holderName":"中国农业银行股份有限公司-中证500交易型开放式指数证券投资基金","totalShare":"1779.13万","sharePercentage":"0.67%"},{"organizationId":"","holderName":"建信基金-杭州银行-华润深国投信托-华润信托·韶夏增利54号单一资金信托","totalShare":"1465.33万","sharePercentage":"0.55%"}],"englishDescription":"Zhejiang CONBA Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of traditional Chinese medicines, modern phytomedicines and chemical drugs. The Company also provides active ingredients. The Company's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The Company also provides value-added services. The Company distributes its products within domestic markets. ","englishIndustry":"Major Drugs","Price to earnings (ttm)":"--","Price to sales (ttm)":"2.37","Price to book (mrq)":"3.20","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"57.81","Lt debt to equity (mrq)":"10.29","Return on investment (ttm)":"-4.21","Return on equity (ttm)":"-2.47","Income statement":{},"Balance sheet":{},"Cash flow":{"Cash receipts":"7,495.10","Cash payments":"(1,526.58)","Cash taxes paid":"(920.72)","Changes in working capital":"(4,122.30)","Cash from operating activities":"925.50","Capital expenditures":"(268.79)","Other investing cash flow items, total":"127.37","Cash from investing activities":"(141.41)","Financing cash flow items":"(242.17)","Total cash dividends paid":"(518.50)","Issuance (retirement) of debt, net":"134.15","Cash from financing activities":"(626.52)","Foreign exchange effects":"(6.04)","Net change in cash":"151.52"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"6.01","52 Week High":"8.30","52 Week Low":"5.01","Pricing date":"","10 Day Average Trading Volume":"61.55","Market Capitalization":"16,030.59","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"1,068.81","Beta":"1.42","1 Day Price Change":"1.52","13 Week Price Return (Daily)":"16.47","26 Week Price Return (Daily)":"-0.99","5 Day Price Return (Daily)":"6.37","52 Week Price Return (Daily)":"-4.15","Year To Date Price Return (Daily)":"-2.28","Month to Date Price Return (Daily)":"9.27","Price Relative to S&P500 (4 Week)":"1.68","Price Relative to S&P500 (13 Week)":"0.64","Price Relative to S&P500 (26 Week)":"-10.96","Price Relative to S&P500 (52 Week)":"-15.77","Price Relative to S&P500 (YTD)":"-9.95"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"-0.13","EPS excl. Extra Items (TTM)":"-0.13","EPS Normalized (Annual)":"0.07","Revenue per Share (Annual)":"2.54","Revenue per Share (TTM)":"2.51","Book Value (Per Share Annual)":"1.81","Book Value (Per Share Quarterly)":"1.88","Tangible Book Value (Per Share Annual)":"1.57","Tangible Book Value (Per Share Quarterly)":"1.64","Cash Per Share (Per Share Annual)":"0.65","Cash Per Share (Per Share Quarterly)":"0.78","Cash Flow (Per Share Annual)":"-0.00","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.00","Dividends (Per Share TTM)":"0.00","EBITD (Per Share TTM)":"0.06","EPS Basic excl. Extra Items (Annual)":"-0.13","EPS Basic excl. Extra Items (TTM)":"-0.13","EPS incl. Extra Items (Annual)":"-0.13","EPS incl. Extra Items (TTM)":"-0.13","Free Cash Flow (Per Share TTM)":"0.07","Dividend (Per Share 5Y)":"0.10"},"Valuation":{"P/E excl. Extra Items (Annual)":"--","P/E excl. Extra Items (TTM)":"--","P/E Normalized (Annual)":"84.20","Price to sales (Annual)":"2.37","Price to sales (TTM)":"2.37","Price to Tangible Book (Annual)":"3.97","Price to Tangible Book (Quarterly)":"3.80","Price to Free Cash Flow (Per Share Annual)":"115.98","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"83.98","Price to Book (Annual)":"3.31","Price to Book (Quarterly)":"3.20","P/E Basic excl. Extra Items (TTM)":"--","P/E excl. Extra Items High (TTM)":"63.11","P/E excl. Extra Items Low (TTM)":"19.37","P/E incl. Extra Items (TTM)":"--","Net Debt (Interim)":"780.88","Net Debt (Annual)":"1,513.45","Dividend Yield (5Y)":"1.38","Dividend Yield":"--","Current Dividend Yield (TTM)":"0.00"},"Financial Strength":{"Free Cash Flow (Annual)":"138.21","Current Ratio (Annual)":"1.12","Net Interest coverage (Annual)":"4.19","Long Term Debt/Equity (Annual)":"10.96","Payout Ratio (Annual)":"--","Quick Ratio (Annual)":"0.82","Total Debt/Total Equity (Annual)":"68.42","Current EV/Free Cash Flow (Annual)":"--","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.18","Long Term Debt/Equity (Quarterly)":"10.29","Quick Ratio (Quarterly)":"0.91","Total Debt/Total Equity (Quarterly)":"57.81","Free Cash Flow (TTM)":"190.88","Net Interest Coverage (TTM)":"0.89","Payout Ratio (TTM)":"--"},"Margins":{"Gross Margin (Annual)":"74.40","Gross Margin (TTM)":"72.11","Net Profit Margin % (Annual)":"-4.01","Net Profit Margin (TTM)":"-3.85","Operating Margin (Annual)":"-0.58","Operating Margin (TTM)":"-0.08","Pretax Margin (TTM)":"-0.41","Pretax Margin (Annual)":"-0.74","Operating Margin (5Y)":"9.72","Pretax Margin (5Y)":"9.95","Free Operating Cash Flow/Revenue (5Y)":"2.02","Free Operating Cash Flow/Revenue (TTM)":"2.82","Gross Margin (5Y)":"65.37","Net Profit Margin (5Y)":"7.20"},"Management Effectiveness":{"Return on Assets (Annual)":"-2.62","Return on Equity (TTM)":"-2.47","Return on Average Equity (Annual)":"-6.68","Return on Average equity (TTM)":"-6.54","Return on Investment (Annual)":"-4.39","Return on Investment (TTM)":"-4.21","Return on Average Assets (5Y)":"4.72","Return on Average Equity (5Y)":"8.74","Return on Investment (5Y)":"7.52","Asset Turnover (Annual)":"0.65","Asset Turnover (TTM)":"0.64","Inventory Turnover (Annual)":"1.40","Inventory Turnover (TTM)":"1.54","Net Income/Employee (Annual)":"-28,812.91","Net Income/Employee (TTM)":"-27,377.21","Receivables Turnover (Annual)":"5.41","Receivables Turnover (TTM)":"4.61","Revenue/Employee (Annual)":"718,235.60","Revenue/Employee (TTM)":"710,455.50"},"Growth":{"Revenue Growth (Quarterly YoY)":"-3.50","Revenue Growth Rate (5Y)":"13.57","EPS Growth (Quarterly YoY)":"-0.94","EPS Growth (TTM YoY)":"-147.36","EPS Growth Rate (5Y)":"--","Dividend Growth Rate (3Y)":"--","Revenue Growth (TTM YoY)":"-3.11","Revenue Growth (Per Share 5Y)":"7.90","Revenue Growth Rate (3Y)":"3.98","EPS Growth Rate (3Y)":"--","Book Value Growth Rate (Per Share 5Y)":"6.06","Tangible Book Value Total Equity CAGR (5Y)":"24.14","Capital Spending growth rate 5 year":"-8.94","EBITDA CAGR (5Y)":"10.68","EBITDA Interim CAGR (5Y)":"-25.11","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"12.44","Net Profit Margin Growth Rate (5Y)":"--"},"Income Statement":{"Revenue (Annual)":"6,768.29","Revenue (TTM)":"6,758.56","EBITD (Annual)":"1,291.03","EBITD (TTM)":"173.12","Earnings Before Taxes (Annual)":"-50.02","Earnings Before Taxes (TTM)":"-27.89","Net Income to Common (Annual)":"-345.63","Net Income to Common (TTM)":"-339.51","Earnings Before Taxes Normalized (Annual)":"774.62","Net Income Available to Common Normalized (Annual)":"190.38","Diluted Normalized EPS excl. Extra Items (TTM)":"-0.13"}}}